曼托细胞淋巴瘤（MCL）是一种罕见的侵袭性非霍奇金淋巴瘤亚型，占据所有病例的5％。由于其凶性因素，它是一种不可治愈的疾病，并在密集治疗方案下持续复发。研究和药物发现的进展已将治疗策略从传统化疗转变为靶向药物和免疫疗法。布鲁顿酪氨酸激酶的角色的确立，导致了第一代BTK抑制剂伊布替尼布的开发，及其继任者。基于调理方案的免疫治疗剂如伊布替莫布也已证明具有良好的毒性剖面下可有效应答。唯一获批的CAR T细胞疗法布雷躄卡自身粒细胞，已证实对儿童和成人的复发/难治性MCL有益。本文回顾了一些可能有助于更新当前方法的治疗方法，并总结了一些少在试验中研究的杂项药物，可以缓解传统治疗中观察到的倒退。数据可获得性：本研究期间生成和/或分析的数据可根据合理的要求从通讯作者那里获得。版权©2023 Elsevier B.V. 保留所有权利。

Mantle cell lymphoma (MCL) is a rare, aggressive subtype of non-Hodgkin's lymphoma (NHL), accounting for 5% of all cases. Due to its virulence factor, it is an incurable disease and keeps relapsing despite an intensive treatment regimen. Advancements in research and drug discovery have shifted the treatment strategy from conventional chemotherapy to targeted agents and immunotherapies. The establishment of the role of Bruton tyrosine kinase led to the development of ibrutinib, a first-generation BTK inhibitor, and its successors. A conditioning regimen based immunotherapeutic agent like ibritumumob, has also demonstrated a viable response with a favorable toxicity profile. Brexucabtagene Autoleucel, the only approved CAR T-cell therapy, has proven advantageous for relapsed/refractory MCL in both children and adults. This article reviews certain therapies that could help update the current approach and summarizes a few miscellaneous agents, which, seldom studied in trials, could alleviate the regression observed in traditional therapies. DATA AVAILABILITY: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.Copyright © 2023 Elsevier B.V. All rights reserved.